Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report-Reference-Cited by-同舟云学术

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Published:2022-12 Issue:12 Volume:3 Page:100432
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Riudavets Mariona,Azarine Arshid,Smaali Sondes,Kim Young-Wouk,Thomas de Montpréville Vincent,Grecea Alina Miruna,Naltet Charles,Gazzah Annas,Planchard David

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019

2. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021;Ettinger;J Natl Compr Canc Netw,2021

3. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations;Riudavets;ESMO Open,2021

4. Topoisomerase I inhibitors: camptothecins and beyond;Pommier;Nat Rev Cancer,2006

5. OA04.05: trastuzumab deruxtecan in HER2-overexpressing metastatic non–small cell lung cancer (NSCLC): interim results of DESTINY-Lung01;Nakagawa;J Thorac Oncol,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance;Biomedicines;2024-04-25

2. Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC;Current Treatment Options in Oncology;2024-03-23

3. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report;Anti-Cancer Drugs;2023-08-25